Acurx Pharmaceuticals LLC Cash Flow-to-Debt Ratio
Acurx Pharmaceuticals LLC cash flow-to-debt ratio. Acurx Pharmaceuticals LLC (ACXP) has a Cash Flow-to-Debt Ratio of -0.60x as of June 2026, meaning its operating cash flow of $-1.71 Million could theoretically repay -1% of its total liabilities ($2.83 Million) in one year. See Acurx Pharmaceuticals LLC (ACXP) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Acurx Pharmaceuticals LLC (2019–2025)
Cash flow-to-debt ratio of Acurx Pharmaceuticals LLC from 2019 to 2025. Historical debt coverage capacity for Acurx Pharmaceuticals LLC across 7 annual periods. Also explore Acurx Pharmaceuticals LLC net asset momentum to track the company's year-over-year net asset growth rate.
Acurx Pharmaceuticals LLC Cash Flow-to-Debt Ratio by Year (2019–2025)
Acurx Pharmaceuticals LLC cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Acurx Pharmaceuticals LLC. For the full cash flow conversion analysis, see Acurx Pharmaceuticals LLC cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.80x | $-6.79 Million | $2.42 Million | ▲ +12.4% |
| 2024 | -3.20x | $-10.38 Million | $3.24 Million | ▲ +0.6% |
| 2023 | -3.22x | $-9.80 Million | $3.04 Million | ▲ +11.9% |
| 2022 | -3.66x | $-7.54 Million | $2.06 Million | ▲ +38.4% |
| 2021 | -5.94x | $-5.01 Million | $843.91K | ▲ +7.4% |
| 2020 | -6.42x | $-3.35 Million | $522.43K | ▼ -175.5% |
| 2019 | -2.33x | $-3.99 Million | $1.71 Million | — |